☆ 4.7 Review

Perspectives on the Efficacy of Benralizumab for Treatment of Eosinophilic Granulomatosis With Polyangiitis

FRONTIERS IN PHARMACOLOGY (2022)

Related references

Note: Only part of the references are listed.

Letter Respiratory System

Benralizumab's anti-eosinophil efficacy may be decreased by impaired NK cell activity

Sophie M. Poznanski et al.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection

Article Respiratory System

Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity

Rania Dagher et al.

Summary: Benralizumab, a humanised monoclonal antibody, shows potent anti-eosinophilic activity through induction of eosinophil apoptosis and phagocytosis by macrophages. The mechanism involves NK cells, macrophage-derived TNF, and activation of Caspase-3/7 and cytochrome c. The afucosylation of benralizumab enhances its potency for these mechanisms.

EUROPEAN RESPIRATORY JOURNAL (2022)

Add to Collection

Article Rheumatology

Rituximab and mepolizumab combination therapy for glucocorticoid-resistant myocarditis related to eosinophilic granulomatosis with polyangiitis

Kana Higashitani et al.

Summary: Eosinophilic granulomatosis with polyangiitis (EGPA), a type of ANCA-associated vasculitides, is characterized by eosinophil-rich inflammation and vasculitis, often associated with asthma and eosinophilia. This case report highlights successful treatment of EGPA-associated myocarditis with a combination of rituximab and mepolizumab after refractory response to glucocorticoid therapy.

MODERN RHEUMATOLOGY CASE REPORTS (2022)

Add to Collection

Letter Rheumatology

Benralizumab as a Potential Adjunctive Therapy in Eosinophilic Granulomatosis With Polyangiitis

Yvonne Lee et al.

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY (2021)

Add to Collection

Article Immunology

Benralizumab in eosinophilic granulomatosis with polyangiitis complicated by Staphylococcus aureus sepsis

Antonios G. A. Kolios et al.

Summary: Eosinophilic Granulomatosis with Polyangiitis (EGPA) is a small-vessels vasculitis associated with ANCA, characterized by hypereosinophilia and eosinophilic asthma. In cases of life-threatening organ involvement, particularly cardiac and central nervous system (CNS), immediate immunosuppression is required. Antibiotic therapy combined with Benralizumab can be a potential therapeutic option for active EGPA with eosinophil-mediated pathologies in severely ill patients.

CLINICAL IMMUNOLOGY (2021)

Add to Collection

Editorial Material Allergy

Efficacy of Benralizumab and Clinical Course of IgG4 in Eosinophilic Granulomatosis With Polyangiitis

Y. Miyata et al.

JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Letter Allergy

The effects of mepolizumab on peripheral circulation and neurological symptoms in eosinophilic granulomatosis with polyangiitis (EGPA) patients

Noboru Kitamura et al.

ALLERGOLOGY INTERNATIONAL (2021)

Add to Collection

Article Allergy

Benralizumab as a Steroid-Sparing Treatment Option in Eosinophilic Granulomatosis with Polyangiitis

Vamsi P. Guntur et al.

Summary: The study demonstrated that benralizumab was well tolerated in patients with EGPA, facilitating reduction in oral corticosteroid dose and decreasing exacerbations. Larger controlled trials are needed to further evaluate the potential role of benralizumab in treating EGPA.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

Add to Collection

Article Respiratory System

Rapid effect of benralizumab in exacerbation of severe eosinophilic asthma associated with eosinophilic granulomatosis with polyangiitis

Carlos Martinez-Rivera et al.

Summary: This case report demonstrates rapid improvement in symptoms and lung function in a patient with severe eosinophilic asthma associated with EGPA using benralizumab. The findings suggest the potential advantage of benralizumab in the treatment of patients with EGPA and severe eosinophilic asthma refractory to conventional treatment.

BMC PULMONARY MEDICINE (2021)

Add to Collection

Article Pediatrics

Pulmonary eosinophilic vasculitis with granulomas and benralizumab in children

Daniel M. Hinds et al.

PEDIATRIC PULMONOLOGY (2021)

Add to Collection

Letter Allergy

Benralizumab restores gene and microRNA expression involved in steroid sensitivity in severe asthma

Keita Hirai et al.

ALLERGY (2021)

Add to Collection

Editorial Material Allergy

Benralizumab: Resolution of Eosinophilic Pulmonary Vasculitis in a Patient With EGPA

S. Bormioli et al.

JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY (2021)

Add to Collection

Article Respiratory System

Successful treatment with benralizumab in a patient with eosinophilic granulomatosis with polyangiitis refractory to mepolizumab

Francesco Menzella et al.

Summary: EGPA is a rare multi-organ inflammatory condition characterized by necrotizing eosinophilic granulomatous inflammation. Effective treatment options include oral glucocorticoids, but frequent relapses and side effects are common. There is currently no consensus on dosing and treatment schedules for managing EGPA.

MULTIDISCIPLINARY RESPIRATORY MEDICINE (2021)

Add to Collection

Article Rheumatology

Successful early introduction of mepolizumab for peripheral neuropathy with a peripheral circulatory disorder in a patient with myeloperoxidase anti-neutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis

Masahiro Nishihara et al.

Summary: In this case, a 26-year-old female patient with EGPA developed peripheral neuropathy. While initial treatment with methylprednisolone and intravenous immunoglobulin led to temporary improvement, symptoms recurred. The introduction of mepolizumab early in the treatment course resulted in significant improvement, suggesting its potential efficacy in progressive peripheral neuropathy associated with eosinophilia.

MODERN RHEUMATOLOGY CASE REPORTS (2021)

Add to Collection

Letter Rheumatology

Emergence of extrathoracic manifestations of eosinophilic granulomatosis with polyangiitis during benralizumab treatment

Andy K. H. Lim et al.

RHEUMATOLOGY ADVANCES IN PRACTICE (2021)

Add to Collection

Letter Respiratory System

Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis

Alexandra M. Nanzer et al.

ERJ OPEN RESEARCH (2021)

Add to Collection

Article Immunology

Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Benralizumab.

María Vanessa Chica-Guzmán et al.

ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2020)

Add to Collection

Review Allergy

The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis

Hiroyuki Nagase et al.

ALLERGOLOGY INTERNATIONAL (2020)

Add to Collection

Letter Allergy

An alternative approach against eosinophils for the treatment of eosinophilic granulomatosis with polyangiitis

Ismael Carrillo-Martin et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)

Add to Collection

Letter Allergy

Early benralizumab for eosinophilic myocarditis in eosinophilic granulomatosis with polyangiitis

Stefania Colantuono et al.

ALLERGOLOGY INTERNATIONAL (2020)

Add to Collection

Letter Allergy

Eosinophilic granulomatosis with polyangiitis evolution during severe eosinophilic asthma treatment with benralizumab

Alojzija Hocevar et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)

Add to Collection

Letter Allergy

Benralizumab as a glucocorticoid-sparing treatment option for severe asthma in eosinophilic granulomatosis with polyangiitis

Roberto Padoan et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)

Add to Collection

Letter Respiratory System

Steroid-sparing effects of benralizumab in patients with eosinophilic granulomatosis with polyangiitis

Alexandra M. Nanzer et al.

ERJ OPEN RESEARCH (2020)

Add to Collection

Article Respiratory System

Rapid onset of effect of benralizumab on respiratory symptoms in a patient with eosinophilic granulomatosis with polyangiitis

Angelo Coppola et al.

RESPIRATORY MEDICINE CASE REPORTS (2020)

Add to Collection

Article Medicine, General & Internal

Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome

F. L. Kuang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Letter Allergy

Decrease in MPO-ANCA after administration of benralizumab in eosinophilic granulomatosis with polyangiitis

Kenchi Takenaka et al.

ALLERGOLOGY INTERNATIONAL (2019)

Add to Collection

Review Allergy

Update on eosinophilic granulomatosis with polyangiitis

Shunsuke Furuta et al.

ALLERGOLOGY INTERNATIONAL (2019)

Add to Collection

Review Allergy

Immunological and hematological effects of IL-5(Rα)-targeted therapy: An overview

M. Hassani et al.

ALLERGY (2018)

Add to Collection

Article Allergy

Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome

Fei Li Kuang et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2018)

Add to Collection

Review Health Care Sciences & Services

Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy

Paola Faverio et al.

THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2018)

Add to Collection

Article Respiratory System

Eosinophilic Lung Diseases

Vincent Cottin

CLINICS IN CHEST MEDICINE (2016)

Add to Collection

Article Respiratory System

The clinical profile of benralizumab in the management of severe eosinophilic asthma

Francesco Menzella et al.

THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE (2016)

Add to Collection

Review Immunology

Churg-Strauss syndrome

Antonio Greco et al.

AUTOIMMUNITY REVIEWS (2015)

Add to Collection

Article Allergy

Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia

Michel Laviolette et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)

Add to Collection

Review Rheumatology

Churg-Strauss syndrome: update on pathophysiology and treatment

Augusto Vaglio et al.

CURRENT OPINION IN RHEUMATOLOGY (2012)

Add to Collection

Letter Medicine, General & Internal

Targeting Interleukin-5 in Refractory and Relapsing Churg-Strauss Syndrome

Frank Moosig et al.

ANNALS OF INTERNAL MEDICINE (2011)

Add to Collection

Article Allergy

MEDI-563, a humanized anti-IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function

Roland Kolbeck et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)

Add to Collection

Article Biochemistry & Molecular Biology

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

T Shinkawa et al.

JOURNAL OF BIOLOGICAL CHEMISTRY (2003)

Add to Collection

Article Critical Care Medicine

Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway

PT Flood-Page et al.

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)

Add to Collection

© Peeref 2019-2024. All rights reserved.